Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study to Investigate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Antisense Oligonucleotide STK-001 in Children and Adolescents With Dravet Syndrome

NCT04442295 is registered in ClinicalTrials.gov with Stoke Therapeutics, Inc as lead sponsor.

NCT NCT04442295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04442295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study to Investigate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Antisense Oligonucleotide STK-001 in Children and Adolescents With Dravet Syndrome
Lead sponsor
Stoke Therapeutics, Inc
Phase
Phase 1/2
Overall status
Completed
Start date
June 29, 2020
Completion date
November 14, 2023
Enrollment
62 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

dravet syndrome